<DOC>
	<DOCNO>NCT00386685</DOCNO>
	<brief_summary>The primary objective study ass activity XRP9881 combination trastuzumab . The secondary objective safety pharmacokinetic interaction</brief_summary>
	<brief_title>XRP9881 Combination With Trastuzumab Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Metastatic breast cancer ( MBC ) HER2 ( Human Epidermal Growth Factor Receptor 2 ) positive : FISH ( Fluorescent In Situ Hybridization ) positive IHC ( Immunohistochemistry ) 3+ Measurable disease accord Response Evaluation Criteria In Solid Tumors ( RECIST ) Adequate organ function More one previous chemotherapy regimen metastatic disease Cardiac dysfunction</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Breast</keyword>
	<keyword>metastatic breast cancer</keyword>
</DOC>